ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

TRX Tissue Regenix Group Plc

57.00
0.00 (0.00%)
Last Updated: 08:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Tissue Regenix Group Plc LSE:TRX London Ordinary Share GB00BNTXR104 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 57.00 55.00 59.00 57.00 57.00 57.00 7,184 08:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 29.49M -302k -0.0043 -132.56 40.23M
Tissue Regenix Group Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker TRX. The last closing price for Tissue Regenix was 57p. Over the last year, Tissue Regenix shares have traded in a share price range of 50.50p to 74.00p.

Tissue Regenix currently has 70,574,468 shares in issue. The market capitalisation of Tissue Regenix is £40.23 million. Tissue Regenix has a price to earnings ratio (PE ratio) of -132.56.

Tissue Regenix Share Discussion Threads

Showing 14076 to 14098 of 14850 messages
Chat Pages: Latest  570  569  568  567  566  565  564  563  562  561  560  559  Older
DateSubjectAuthorDiscuss
28/4/2022
10:10
A few more snips of info and presentations from the company will soon have a major positive impact.

It is interesting to watch the MM game going on today and it seems the doors open once again.

clocktower
28/4/2022
07:55
About Neil Hunt:



Encouraging to have such a qualified participant.

cliffpeat
28/4/2022
07:54
GSG, I am not surprised but I can only set my target on the research and information that I have received. However I do not doubt that you maybe correct, and I may up my target as more information and results becomes available, as this is now a longer term hold for me.

MM keeping the lid shut this morning, I believe they may be very short of stock.

clocktower
28/4/2022
07:30
clocktower.

Having met the top team earlier this week, my target is double yours.

gsg
28/4/2022
07:11
I like the way they have released this news, very understated. I expect it will soon attract the micro fund managers, as the presentation to such a massive market will have such a positive effect.

I am now raising my target to 1p.

I am pleased that I had another nibble yesterday
.

clocktower
28/4/2022
06:54
A massive market indeed for OrthoPure®XT.
gsg
28/4/2022
06:18
A massive market that is cruciate ligament repair if this becomes the go to treatment it will be huge in its own right the war aspect could also be advents Gould to TRX
tnt99
27/4/2022
09:02
The sort of medical supplies TRX supplies must be in huge demand from the medics that have to treat the poor souls that are suffering from Russian aggression. I wonder if the international medical aid given to Ukraine would include many of the wound healing products produced by TRX?
clocktower
26/4/2022
15:58
The US market dragging almost everything down today it seems, with this slipping on relatively small volume but with the notice of the results of the votes at the AGM out of the way, I expect that as soon as the market bucks up, we will see a rapid turnaround with some micro cap major investors giving this a good look over, and maybe adding it to their portfolios, as it looks well placed to move up quickly on any news of a good contract or two.
clocktower
25/4/2022
11:23
Your nibble being bigger than mine today and a fraction cheaper mark. Well done.

Don't forget The AGM will be held at DLA Piper, 160 Aldersgate St, Barbican, London EC1A 4HT, on Tuesday 26 April 2022 at 1.00pm.

I guess the felling expressed will be very positive tomorrow.

clocktower
25/4/2022
11:01
I thought I would have another little nibble, as its weak today 250k - 0.51 shows as a sell on ADVFN.

Director buying the other day at over 0.54 with a good outlook. If it drops further, I go for another bite of the cherry.

clocktower
22/4/2022
07:05
Another director buy good to see and could move the share back to 1p by Christmas still very cheap at the mo
tnt99
21/4/2022
13:22
I hope it gets there well before 5 years CarrotandStick.

I am well in the Blue with this one, and will keep adding on weakness now.

It would not surprise me to find out that another director is buying, as a few of the MM's have taken on a lot of stock before dropping the bid while still keeping the offer, to shake out a few more. So a little dip before the next big step and maybe news in May to help it on its way.

clocktower
21/4/2022
06:06
I'm going to hold you to that Clocktower!
carrotandstick
20/4/2022
20:20
10 plus imo. The groundwork is done, the growth will flow.
clocktower
20/4/2022
16:56
A few million shares for just a few thou, doesn't it make you want to buy some. I like the consensus that TRX has negotiated the bottom, prospects are all upwards from here, I would love to understand how big a market they could grow in to and at what margin.

What I mean to ask, is the 3-5 year horizon x 2 or x 10?

marktime1231
20/4/2022
15:28
Another decent director buy.
clocktower
19/4/2022
12:27
It's good to see the two way trade and a few larger blocks being sold, as profits are taken and a new platform of .53 - .55 is being built as a solid base before taking the next step up towards a first target of .70

There is plenty of PI support and as you say quazie12, if a couple of microcaps start building a stake this could move well past my first target quickly.

Is there a chart expert following the thread that could comment on the recent and likely upward movement?

clocktower
19/4/2022
12:00
Thanks for the link GSG - Great report and well worth reading in full.
clocktower
19/4/2022
10:31
Just need a couple more microcap funds to start stake building as this moves towards ebitda breakevwn and profitability
quazie12
19/4/2022
10:30
They value coy on 4 * 2023 forecast revenues 90m sterling or roughly 1.25p
quazie12
19/4/2022
06:43
Hardman & Co Research on Tissue Regenix (TRX): On pathway to sustainability

Tissue Regenix (TRX) is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL) and bone (BioRinse). It has a broad portfolio of commercial regenerative medicine products for the biosurgery, orthopaedics and dental markets. 2021 results contained the early benefits of TRX's strategic activities over the past two years - the focus on commercial relationships, capacity expansion, restructuring to service demand and recovery in elective surgeries. On the basis of continued sales progression, TRX is forecast to become EBITDA-positive in fiscal 2022 and cash-generative in 2023.

Please click on the link below for the full report:

gsg
14/4/2022
12:30
https://audioboom.com/posts/8066986-vadim-alexandre-talks-about-tissue-regenix-polarean-s-new-ned
bloomberg2
Chat Pages: Latest  570  569  568  567  566  565  564  563  562  561  560  559  Older

Your Recent History

Delayed Upgrade Clock